Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab

Table 3 Change in CMT at each time point following transition to aflibercept therapy

Time point	CMT^a (Mean ± SD)	Change from Baseline (Mean ± SD)	Change from Baseline (%)	P-value^b	95% CI
Time point	CMT^a (Mean ± SD)	Change from Baseline (Mean ± SD)	Change from Baseline (%)	P-value^b	Lower	Upper
Baseline	387 ± 99
Month 1	326 ± 90	− 64 ± 75	15	< 0.0001	85	− 43
Month 3	345 ± 88	− 42 ± 85	8	0.002	− 66	− 18
Month 6	341 ± 96	− 47 ± 69	11	< 0.0001	− 66	− 28
Month 12	342 ± 96	− 46 ± 99	9	0.001	− 73	− 18

CMT central macular thickness, CI: confidence interval
^a μM
^b Based on hybrid linear mixed model, adjusted for multiple comparisons based on Sidak method

ISSN: 2056-9920